The AB4AD Story
Expert Researchers
Under the leadership of Dr. Daniel Z. Bar from Tel Aviv University, our research team is pioneering innovative approaches to understanding and combating Alzheimer's Disease.
With extensive experience in neurodegenerative disease research, our team brings together expertise in immunology, neuroscience, and biotechnology.
The Research Journey
Having learnt about the overwhelming evidence that supports the Pathogen Hypothesis, we have dedicated ourselves to unravelling the causes behind Alzheimer's development. Two pathogens of special interest emerged: herpes (the common cold sore) and P.gingivalis (gum disease), both shown to significantly impact AD risk.
Through our partnership with Fliman Geriatric Hospital and the university's dental school, we've already identified promising differences in antibody levels between AD and non-AD samples.
Future Vision
Our research aims to develop two groundbreaking solutions: a diagnostic tool for early AD detection and a potential vaccine. The diagnostic tool will enable non-invasive, early diagnosis of asymptomatic individuals, while our long-term goal focuses on vaccine development.
With $192,570 USD in funding, we'll expand our sample screening, perform advanced VirScan analysis, and validate protein-protein interactions crucial to the immune response.
Commercial Potential
Our commercialization strategy follows a two-step approach: first, developing a diagnostic tool for quick market entry, followed by vaccine development. This approach allows us to generate early revenue while gathering crucial data for vaccine research.
We're securing patents for our diagnostic kit components and future vaccine development, ensuring long-term value for our stakeholders while advancing global healthcare.
